| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2011 |
| Sales | 30,620 | 21,740 | 275,760 | 0 | 5,351,510 |
| Sales Growth | +40.85% | -92.12% | unch | -100.00% | -8.70% |
| Net Income | -46,300 | -62,720 | -190,450 | -3,310 | -520,290 |
| Net Income Growth | +26.18% | +67.07% | -5,653.78% | +99.36% | -161.03% |
Prenetics Global Limited Class A Ordinary Share (PRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Prenetics, a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Their prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, their joint venture with renowned scientist Prof. Dennis Lo, underscores their unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Lastly, ACT Genomics, their treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics' units synergistically enhances their global impact on health, truly embodying their commitment to 'enhancing life through science'.
Fiscal Year End Date: 12/31